Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Total Liabilities (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Total Liabilities for 13 consecutive years, with $106.3 million as the latest value for Q1 2026.

  • For Q1 2026, Total Liabilities rose 429.64% year-over-year to $106.3 million; the TTM value through Mar 2026 reached $106.3 million, up 429.64%, while the annual FY2025 figure was $76.7 million, 173.39% up from the prior year.
  • Total Liabilities hit $106.3 million in Q1 2026 for Viking Therapeutics, up from $76.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $106.3 million in Q1 2026 and bottomed at $12.8 million in Q1 2022.
  • Average Total Liabilities over 5 years is $30.0 million, with a median of $23.2 million recorded in 2022.
  • Year-over-year, Total Liabilities tumbled 40.3% in 2025 and then surged 429.64% in 2026.
  • Viking Therapeutics' Total Liabilities stood at $23.2 million in 2022, then decreased by 13.51% to $20.1 million in 2023, then soared by 39.72% to $28.0 million in 2024, then surged by 173.39% to $76.7 million in 2025, then surged by 38.68% to $106.3 million in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $106.3 million, $76.7 million, and $26.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.